Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 5, 2000, Pages 1895-1900

  Fogelman, Ignac ^a   Ribot, Claude ^b   Smith, Roger ^c   Ethgen, Dominique ^d   Sod, Earl ^d   Reginster, Jean Yves ^e  

^a GUY S HOSPITAL   (United Kingdom)

^b CHU RANGUEIL   (France)

^c Acland Hospital   (United Kingdom)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e Polyclinique L Brull   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CREATININE; ETIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; FEMUR NECK; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER;

AGED; BONE DENSITY; CALCIUM; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; EUROPE; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; TIME FACTORS;

EID: 17744382186     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.5.1895     Document Type: Article

References (38)

1. The prevention and treatment of osteoporosis
2. Estrogen deficiency
3. A critical review of bone mass and the risk of fractures in osteoporosis
4. Long-term fracture prediction by bone mineral assessed at different skeletal sites
5. What constitutes evidence for drug efficacy in osteoporosis?
6. Epidemiology of osteoporosis and osteoporotic fractures
7. The cost of treating osteoporotic fractures in the United Kingdom female population
8. Treatment of postmenopausal osteoporosis with transdermal estrogen
9. Estrogen replacement therapy and fractures in older women
10. Compliance with hormone therapy
11. Prevalence, initiation, and continuation of hormone replacement therapy
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
13. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
14. Bisphosphonates in the treatment of osteoporosis in 1997: A review
15. Clinical practice guidelines for the diagnosis and management of osteoporosis
16. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
17. Early postmenopausal bone loss and intermittent cyclical etidronate therapy
18. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial
19. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy
20. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
21. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
22. Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study
23. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease
24. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
25. Risedronate therapy prevents corticosteroid-induced bone loss
26. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis
27. Universal standardization for dual x-ray absorptiometry: Patient and phantom cross-calibration results
28. Quality control of DXA instruments in multicenter trials
29. Assessing vertebral fractures
30. Prevalence and incidence of vertebral deformities
31. Risedronate prevention of bone loss in early postmenopausal women
32. Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass
33. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
34. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
35. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation
36. Esophagitis associated with the use of alendronate
37. Multiple ulcerative esophagitis caused by alendronate